TGFB1 and myelofibrosis: In particular, Komura et al.33 have speculated a role of NF-κB pathway in transforming growth factor-beta1 production in PMF; Wagner-Ballon et al.34 have reported as Bortezomib, a proteasome inhibitor, impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.